Stockscreener 앱 받기
34.87
3.23%
1.09
시간 외 거래:
35.00
0.13
+0.37%
전일 마감가:
$33.78
열려 있는:
$34.63
하루 거래량:
1.24M
Relative Volume:
1.58
시가총액:
$2.06B
수익:
$184.42M
순이익/손실:
$-6.89M
주가수익비율:
-234.81
EPS:
-0.1485
순현금흐름:
$44.92M
1주 성능:
+9.00%
1개월 성능:
-1.72%
6개월 성능:
+14.33%
1년 성능:
+491.02%
1일 변동 폭
$34.44
$36.31
1주일 범위
$30.66
$36.31
52주 변동 폭
$5.35
$40.22
Stoke Therapeutics Inc Stock (STOK) Company Profile
명칭
Stoke Therapeutics Inc
전화
781-430-8200
주소
45 WIGGINS AVENUE, BEDFORD, MA
Compare STOK vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
34.87 | 2.00B | 184.42M | -6.89M | 44.92M | -0.1485 |
VRTX
Vertex Pharmaceuticals Inc
|
443.92 | 109.85B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
775.53 | 80.38B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
785.07 | 47.60B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
327.25 | 42.63B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.19 | 33.72B | 5.36B | 287.73M | 924.18M | 2.5229 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2026-02-05 | 개시 | Guggenheim | Buy |
| 2026-01-05 | 재개 | Chardan Capital Markets | Buy |
| 2025-07-18 | 개시 | Jefferies | Buy |
| 2024-12-20 | 개시 | Chardan Capital Markets | Buy |
| 2024-10-14 | 재개 | Leerink Partners | Outperform |
| 2024-03-26 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | 재개 | JP Morgan | Neutral |
| 2023-07-25 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-04-26 | 재개 | Canaccord Genuity | Buy |
| 2023-01-06 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2022-10-24 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | 개시 | Jefferies | Buy |
| 2021-12-03 | 개시 | BofA Securities | Buy |
| 2021-11-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-05-18 | 개시 | UBS | Neutral |
| 2021-05-10 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-02-10 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-12-15 | 재개 | H.C. Wainwright | Buy |
| 2020-12-11 | 재확인 | Needham | Buy |
| 2020-10-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-09-29 | 재개 | JP Morgan | Neutral |
| 2020-09-29 | 개시 | Needham | Buy |
| 2019-12-18 | 개시 | Wedbush | Outperform |
| 2019-11-12 | 개시 | BTIG Research | Buy |
| 2019-10-25 | 개시 | H.C. Wainwright | Buy |
| 2019-07-15 | 개시 | Canaccord Genuity | Buy |
| 2019-07-15 | 개시 | Cowen | Outperform |
| 2019-07-15 | 개시 | Credit Suisse | Outperform |
| 2019-07-15 | 개시 | JP Morgan | Overweight |
모두보기
Stoke Therapeutics Inc 주식(STOK)의 최신 뉴스
Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference - Yahoo Finance Singapore
Stoke Therapeutics Appoints Clare Kahn, Ph.D. to Board and Advances Zorevunersen for Dravet Syndrome Treatment - Minichart
Stoke Therapeutics : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
Stoke Therapeutics (STOK) director receives 30,782-share stock option grant - Stock Titan
Stoke Therapeutics (STOK) director Kahn Clare submits initial Form 3 insider report - Stock Titan
Stoke Therapeutics appoints Clare Kahn to board of directors By Investing.com - in.investing.com
Stoke Therapeutics Adds Veteran Leader to Board, R&D Oversight - TipRanks
Clare Kahn joins Stoke Therapeutics (Nasdaq: STOK) board, receives option grant - Stock Titan
Stoke Therapeutics, Inc. Appoints Clare Kahn as Directors and to Serve on Nominating and Corporate Governance Committee and as Chairperson of the Research and Development Committee of the Board, Effective April 3, 2026 - marketscreener.com
Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors - Business Wire
Trading Recap: Can Stoke Therapeutics Inc grow without external fundingQuarterly Market Summary & Technical Entry and Exit Tips - baoquankhu1.vn
Stoke Therapeutics Auditor Switch Puts Biotech Governance In Focus - Yahoo Finance
Growth Value: What is the earnings history of Stoke Therapeutics Inc2026 Major Catalysts & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
Insider Sell Alert: Barry Ticho Sells Shares of Stoke Therapeuti - gurufocus.com
Stoke Therapeutics (STOK) CMO sells 1,838 shares in planned open-market trade - Stock Titan
(STOK) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Stoke Therapeutics (STOK) Price Target Increased by 16.51% to 28.79 - MSN
Insider sells shares under 10b5-1 — STOK (NASDAQ: STOK) discloses trades - Stock Titan
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of "Moderate Buy" from Analysts - marketbeat.com
STOK Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Stoke Therapeutics (STOK) price target increased by 12.11% to 43.96 - MSN
Stoke Therapeutics Hits Day High with 7.98% Surge in Strong Intraday Performance - marketsmojo.com
Stoke Therapeutics Stock Up 340% as Chair Sells $174K in Shares - AOL.com
Stoke Therapeutics, Inc. Files 8-K Announcing Change in Certifying Accountant – March 2026 - minichart.com.sg
Stoke Therapeutics (NASDAQ: STOK) replaces KPMG with EY as auditor - stocktitan.net
Vanguard reports zero Stoke Therapeutics holdings (STOK) - stocktitan.net
Big Money Moves: What hedge funds are buying Stoke Therapeutics Inc2026 Update & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Stoke Therapeutics (NASDAQ:STOK) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
Whale Trades: What is the earnings history of Stoke Therapeutics IncAnalyst Upgrade & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Assenagon Asset Management S.A. Boosts Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Gains Recap: How does Stoke Therapeutics Inc score in quality rankings2026 Historical Comparison & Expert Curated Trade Setups - baoquankhu1.vn
Allan Jonathan, Stoke Therapeutics general counsel, sells $313k in STOK stock - Investing.com Canada
Stoke Therapeutics Insider Sold Shares Worth $313,038, According to a Recent SEC Filing - MarketScreener
Stoke Therapeutics (STOK) counsel sells 9,293 shares under 10b5-1 plan - Stock Titan
Stoke Therapeutics CMO Sells $457,000 in Stock Amid 300% Rally - Yahoo Finance
(STOK) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
FY2030 Earnings Estimate for STOK Issued By HC Wainwright - MarketBeat
Stoke Therapeutics Hits Day Low at $33.50 Amid Price Pressure - Markets Mojo
Stoke earnings loom as analysts bet big on Dravet therapy potential By Investing.com - Investing.com Australia
Stoke earnings loom as analysts bet big on Dravet therapy potential - Investing.com
Stoke Therapeutics (NASDAQ:STOK) Stock Rating Lowered by Wall Street Zen - MarketBeat
Form 144 STOKE THERAPEUTICS INC For: 20 March By Investing.com - Investing.com Canada
Form 144 STOKE THERAPEUTICS INC For: 20 March - Investing.com
Canaccord Genuity Group Forecasts Strong Price Appreciation for Stoke Therapeutics (NASDAQ:STOK) Stock - MarketBeat
Jonathan Allan plans sale of 9,293 RSUs at STOK (NASDAQ: STOK) - Stock Titan
Stoke Therapeutics stock price target raised to $60 by Canaccord on higher revenue assumptions - Investing.com Australia
Stoke Therapeutics Insider Sold Shares Worth $456,835, According to a Recent SEC Filing - marketscreener.com
Stoke Therapeutics Insider Sold Shares Worth $285,901, According to a Recent SEC Filing - marketscreener.com
Leggett, Stoke Therapeutics CFO, sells $147k in STOK stock By Investing.com - Investing.com Australia
Stoke Therapeutics’ chief medical officer Ticho sells shares worth $413k - Investing.com India
Allan, Jonathan, Stoke Therapeutics general counsel, sells $285k in STOK - Investing.com India
Stoke Therapeutics Inc (STOK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.51%
1.75%
자본화:
|
볼륨(24시간):